Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HIV vaccine in worldwide trial

08.10.2003


Vanderbilt is one of nine US sites



Vanderbilt University Medical Center is participating in worldwide tests of a potential vaccine that can stimulate important immune responses against the virus that causes AIDS.

This is the first candidate vaccine against the human immunodeficiency virus (HIV) to be studied simultaneously in so many locations, from Brazil to Thailand, according to Merck & Co. Inc., which developed the vaccine.


Vanderbilt currently is testing six potential AIDS vaccines, but the Merck product has gone farther than any other in generating cellular immune responses in preliminary human tests, says Dr. Paul Spearman, co-principal investigator of the Vanderbilt HIV Vaccine Program, one of nine U.S. sites to participate in the study.

Cellular immune responses refer to the production of a type of white blood cell, known as a cytotoxic or "killer" T-cell, which can clear its virus-infected neighbors from the bloodstream. Scientists believe that by speeding up production of these cells, a vaccine may be able to prevent the virus from spreading in the body.

"It may not prevent infection, but it might stimulate a response that would prevent the disease that results from the infection," Spearman says.

The Vanderbilt program is part of the federally funded HIV Vaccine Trials Network, an international coalition of scientists and institutions dedicated to accelerating the search for an HIV vaccine. This is the first collaboration between Merck and the network. The phase I trial is designed to test – at varying doses -- the vaccine’s safety and ability to stimulate immune responses in healthy, uninfected volunteers between the ages of 18 and 50. Of the 435 volunteers who will participate in the study worldwide, about a dozen will be tested at Vanderbilt.

Volunteers will be randomly selected to receive three injections of the either the vaccine or an inactive "placebo." The study involves 24 clinic visits and 22 blood tests over the course of 18 months.

A goal of the study is to see whether a single vaccine can generate significant immune responses in diverse populations throughout the world. If the trial is successful, more extensive testing will be conducted, ultimately leading to studies in people at risk of being infected with HIV.

The research is moving "fairly quickly," Spearman says. "We’re really hopeful."

The vaccine consists of a synthetically produced HIV gene – which cannot cause HIV infection. The gene is carried by an adenovirus, which normally can cause symptoms of the common cold, but which has been genetically altered so that is harmless. Side effects of the vaccine in preliminary human studies have been mild. They include soreness at the injection site and, at higher doses than will be used in this study, flu-like symptoms in some people.

Clinton Colmenares | EurekAlert!
Further information:
http://www.hivvaccineresearch.com
http://www.mc.vanderbilt.edu/reporter/

More articles from Health and Medicine:

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

nachricht Penn study identifies new malaria parasites in wild bonobos
21.11.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

Water cooling for the Earth's crust

23.11.2017 | Earth Sciences

Nano-watch has steady hands

23.11.2017 | Physics and Astronomy

Batteries with better performance and improved safety

23.11.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>